Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Study to Assess the Safety, Tolerability, and Efficacy of Axelopran Administered With Standard of Care Pembrolizumab in Recurrent/Metastatic HNSCC Patients Taking Opioids to Control Cancer Pain

NCT07662720 is registered in ClinicalTrials.gov with Glycyx Therapeutics as lead sponsor.

NCT NCT07662720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Study to Assess the Safety, Tolerability, and Efficacy of Axelopran Administered With Standard of Care Pembrolizumab in Recurrent/Metastatic HNSCC Patients Taking Opioids to Control Cancer Pain
Lead sponsor
Glycyx Therapeutics
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
August 31, 2028
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m)